Head-To-Head Review: Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Cartesian Therapeutics (NASDAQ:RNAC)

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Risk and Volatility

Eupraxia Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Eupraxia Pharmaceuticals and Cartesian Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1	1	5	2	2.89
Cartesian Therapeutics	1	0	5	0	2.67

Eupraxia Pharmaceuticals currently has a consensus target price of $18.33, suggesting a potential upside of 158.22%. Cartesian Therapeutics has a consensus target price of $33.00, suggesting a potential upside of 388.89%. Given Cartesian Therapeutics’ higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Eupraxia Pharmaceuticals.

Earnings and Valuation

This table compares Eupraxia Pharmaceuticals and Cartesian Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58 million	($1.05)	-6.76
Cartesian Therapeutics	$2.80 million	70.83	-$130.30 million	($5.90)	-1.14

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Cartesian Therapeutics. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eupraxia Pharmaceuticals and Cartesian Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Insider & Institutional Ownership

87.0% of Cartesian Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cartesian Therapeutics beats Eupraxia Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.